It is indicated for patients aged ≥2 years with obesity due to proopiomelanocortin (POMC), PCSK1, leptin receptor (LEPR) deficiencies, or Bardet-Biedl syndrome (BBS), with dosing adjusted by age and weight [24]. Here, POMC is linked to obesity due to melanocortin 4 receptor deficiency.